Impaired humoral immunity following COVID-19 vaccination in HTLV-1 carriers

Takuro Kameda,Atae Utsunomiya,Nobuaki Otsuka,Yoko Kubuki,Taisuke Uchida,Kotaro Shide,Ayako Kamiunten,Nobuaki Nakano,Masahito Tokunaga,Takayoshi Miyazono,Yoshikiyo Ito,Kentaro Yonekura,Toshiro Kawakita,Keiichi Akizuki,Yuki Tahira,Masayoshi Karasawa,Tomonori Hidaka,Ayaka Konagata,Norifumi Taniguchi,Yuma Nagatomo,Fumiko Kogo,Koichiro Shimizu,Hiroaki Ueno,Junzo Ishizaki,Naoya Takahashi,Yoshihiko Ikei,Michihiro Hidaka,Hideki Yamaguchi,Kazuya Shimoda
DOI: https://doi.org/10.1186/s12879-024-09001-z
IF: 3.7
2024-01-18
BMC Infectious Diseases
Abstract:Whether human T-lymphotropic virus type 1 (HTLV-1) carriers can develop sufficient humoral immunity after coronavirus disease 2019 (COVID-19) vaccination is unknown.
infectious diseases
What problem does this paper attempt to address?